Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
131,900
Employees131,900
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
131,900
Employees131,900

JNJ Key Statistics

Market cap
368.70B
Market cap368.70B
Price-Earnings ratio
26.45
Price-Earnings ratio26.45
Dividend yield
3.21%
Dividend yield3.21%
Average volume
8.89M
Average volume8.89M
High today
$154.49
High today$154.49
Low today
$152.81
Low today$152.81
Open price
$153.66
Open price$153.66
Volume
6.20M
Volume6.20M
52 Week high
$168.85
52 Week high$168.85
52 Week low
$140.68
52 Week low$140.68

JNJ News

Seeking Alpha 3d
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy

Dr. Reddy’s (NYSE:RDY) on Thursday announced a licensing agreement with China-based Shanghai Henlius Biotech (OTCPK:SGBCF) to jointly develop and market a biosi...

Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Simply Wall St 3d
Do Its Financials Have Any Role To Play In Driving Johnson & Johnson's Stock Up Recently?

Johnson & Johnson's (NYSE:JNJ) stock is up by a considerable 7.7% over the past month. We wonder if and what role the company's financials play in that price ch...

Do Its Financials Have Any Role To Play In Driving Johnson & Johnson's Stock Up Recently?
Seeking Alpha 6d
J&J gets positive EU opinion for subcutaneous Rybrevant

EU regulators have issued a positive opinion for the extension of the market authorization for a subcutaneous formulation of Johnson & Johnson's (NYSE:JNJ) Rybr...

J&J gets positive EU opinion for subcutaneous Rybrevant

Analyst ratings

52%

of 23 ratings
Buy
47.8%
Hold
52.2%
Sell
0%

More JNJ News

TipRanks 6d
Johnson & Johnson price target raised to $166 from $162 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the shares after updating the...

The Motley Fool 7d
Is Johnson & Johnson Stock a Buy?

Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would...

Is Johnson & Johnson Stock a Buy?
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.